70 193

Cited 1 times in

Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features

Authors
 Kwai Han Yoo  ;  Dok Hyun Yoon  ;  Hye Jin Kang  ;  Won Sik Lee  ;  Kihyun Kim  ;  Jin Seok Kim  ;  Jeong-A Kim  ;  Sung-Hyun Kim  ;  Jae-Yong Kwak  ;  Yang Soo Kim  ;  Chang-Ki Min  ;  Je-Jung Lee  ;  Sung-Soo Yoon  ;  Cheolwon Suh  ;  Rachid Baz  ;  Jae Hoon Lee 
Citation
 CURRENT PROBLEMS IN CANCER, Vol.46(1) : 100788, 2022-02 
Journal Title
CURRENT PROBLEMS IN CANCER
ISSN
 0147-0272 
Issue Date
2022-02
MeSH
Aged ; Humans ; Lenalidomide* / adverse effects ; Multiple Myeloma* / diagnosis ; Multiple Myeloma* / drug therapy ; Progression-Free Survival
Keywords
Corticosteroids ; Lenalidomide ; Myeloma ; Older adults ; Response-adapted therapy
Abstract
Lenalidomide and low-dose dexamethasone (Rd) are a standard treatment for older adults with multiple myeloma (MM). Lenalidomide monotherapy has rarely been evaluated for newly diagnosed transplant-ineligible MM patients. This multicenter phase II trial evaluated a response-adapted strategy for elderly patients with newly diagnosed MM without high-risk features. Patients were administered single-agent lenalidomide for the first 21 days of two 28-day cycles. Patients with progressive disease received Rd. The primary endpoint was progression-free survival using the uniform response assessment from the International Myeloma Working Group . Of the 34 enrolled patients, 28 were included in the efficacy analysis. The overall response rate (ORR, ≥ partial response [PR]) to single-agent lenalidomide or lenalidomide plus prednisone was 64.3%. Ten patients received Rd after disease progression, with an Rd ORR of 70%. The ORR of response-adapted lenalidomide-based therapy was 75%. After the median follow-up of 35.6 months, the median progression-free survival was 33.5 months (95% confidence interval [CI], 16.9-50.2), and the median overall survival was 51.8 months (95% CI, 22.0-81.6). The most common adverse event was neutropenia (46.7%), and 17 patients (56.7%) experienced infection including pneumonia. Response-adapted lenalidomide-based therapy was feasible in newly diagnosed, transplant-ineligible MM patients without high-risk features.
Files in This Item:
T202205268.pdf Download
DOI
10.1016/j.currproblcancer.2021.100788
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/191232
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links